The medical technology firm Cognito Therapeutics has presented new research findings at the 18th Clinical Trials on Alzheimer’s Disease (CTAD) conference concerning its experimental non-invasive device therapy for Alzheimer's disease. This innovation is dubbed Spectris™.
The presented data, which was derived from two separate studies, indicates that use of the device was associated with measurable biochemical changes in cerebrospinal fluid, specifically an increase in a protein linked to synaptic health and plasticity, alongside alterations in other proteins involved in neural protection. Additionally, electroencephalogram readings from a clinical trial suggested the non-invasive device therapy may slow the progression of certain brain wave patterns characteristic of the disease.
Christian Howell, CEO, Cognito Therapeutics, confirmed: "The data presented at CTAD strengthen the biological foundation behind Spectris™ and show that a non-invasive, at-home therapy can engage pathways central to brain resilience and health."
Non-Invasive Alzheimer's Therapies
Cognito Therapeutics Presents Its Non-Invasive Device Therapy
Trend Themes
-
Non-invasive Neuromodulation — Emerging non-invasive therapies offer innovative neuromodulation techniques that target neurological diseases like Alzheimer’s without the need for surgical intervention.
-
Home-based Health Devices — Portable and at-home health devices are transforming patient care by providing continuous treatment in a familiar and comfortable setting, making healthcare more accessible.
-
Biochemical Biomarker Monitoring — Advancements in monitoring biochemical markers in cerebrospinal fluid are enhancing our understanding of synaptic health and neural protection, paving the way for precision medicine.
Industry Implications
-
Medical Technology — The medical technology industry is witnessing a revolution with the development of devices that leverage non-invasive methods to treat chronic neurological conditions.
-
Home Healthcare — The home healthcare sector is evolving as new technologies enable patients to receive treatment in the comfort of their own homes, increasing convenience and compliance.
-
Biotech and Pharmaceuticals — Biotech and pharmaceutical companies are increasingly focusing on biomarker-driven strategies to develop targeted therapies that improve patient outcomes in neurological diseases.